Back to top
more

Axsome Therapeutics (AXSM)

(Real Time Quote from BATS)

$103.43 USD

103.43
275,062

-0.16 (-0.15%)

Updated Aug 6, 2025 02:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

by Zacks Equity Research

Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.

Zacks Equity Research

Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Axsome (AXSM) delivered earnings and revenue surprises of +8.00% and +7.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ALKS Down Despite Positive Top-Line Data From Narcolepsy Study

by Zacks Equity Research

Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.

Sundeep Ganoria headshot

Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment

by Sundeep Ganoria

HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.

Zacks Equity Research

Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

by Zacks Equity Research

Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.

Zacks Equity Research

Axsome (AXSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Axsome (AXSM) delivered earnings and revenue surprises of 36.51% and 1.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline

by Zacks Equity Research

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last?

by Zacks Equity Research

Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Ekta Bagri headshot

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

by Ekta Bagri

CORT and AXSM are in the spotlight this week following the announcement of study data.

Zacks Equity Research

AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol

by Zacks Equity Research

Axsome's phase III PARADIGM study evaluating solriamfetol in major depressive disorder fails to show a statistically significant change in the primary endpoint.

Zacks Equity Research

Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680

by Zacks Equity Research

ALKS' phase II Vibrance-3 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with idiopathic hypersomnia.

Zacks Equity Research

AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint

by Zacks Equity Research

Axsome's phase III FOCUS study, evaluating solriamfetol for treating attention deficit hyperactivity disorder, meets its primary and key secondary endpoints.

Zacks Equity Research

Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ekta Bagri headshot

HRMY Down 10.8% in Six Months: How Should You Play the Stock?

by Ekta Bagri

A recent regulatory setback has hit Harmony Biosciences stock. We recommend prospective investors to wait for a while before turning positive.

Zacks Equity Research

Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?

by Zacks Equity Research

Axsome's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. The recent FDA nod for Symbravo also bodes well.

Zacks Equity Research

AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals

by Zacks Equity Research

Axsome enters into a settlement agreement with Hikma Pharmaceuticals to resolve a patent litigation related to Sunosi.

Zacks Equity Research

AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug Filing

by Zacks Equity Research

Based on the FDA's feedback, Axsome plans to submit a supplemental NDA for AXS-05 in Alzheimer's disease agitation in third-quarter 2025.

Zacks Equity Research

Axsome Q4 Loss Wider Than Expected, Auvelity Drives Sales Growth

by Zacks Equity Research

AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.

Zacks Equity Research

Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Axsome (AXSM) delivered earnings and revenue surprises of 4% and 0.74%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?